Dosing of cytotoxic chemotherapy: Impact of renal function estimates on dose

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2746-2752

  Dooley, M J ^a,b   Poole, S G ^a,b   Rischin, D ^c,d  

^a Alfred Health ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Carboplatin; Chemotherapy; Dose; Glomerular ltration rate; Renal function

Indexed keywords

CARBOPLATIN; CYTOTOXIC AGENT; PENTETATE TECHNETIUM TC 99M;

4 VARIABLE MODIFICATION OF DIET IN RENAL DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION FORMULA; COCKCROFT AND GAULT FORMULA; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE CLASSIFICATION; DOSE KIDNEY FUNCTION RELATION; FEMALE; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HUMAN; KIDNEY FUNCTION TEST; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; PRIORITY JOURNAL; URINARY EXCRETION; WRIGHT AND MARTIN FORMULA;

CARBOPLATIN; CHEMOTHERAPY; DOSE; GLOMERULAR FILTRATION RATE; RENAL FUNCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CREATININE; DRUG DOSAGE CALCULATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY;

EID: 84887062810     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt300     Document Type: Article

References (33)

1. Launay-Vacher V, Oudard S, Janus N et al. Prevalence of renal insuf ciency in cancer patients and implications for anticancer drug management: the renal insufciency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384.
2. Lichtman SM, Wildiers H, Launay-Vacher V et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufciency. Eur J Cancer 2007; 43: 14-34.
3. Launay-Vacher V, Chatelut E, Lichtman SM et al. Renal insufciency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007; 18: 1314-1321.
4. Lamb E. Assessment of kidney function in adults. Medicine 2011; 39: 306-311.
5. Traynor J, Mactier R, Geddes CC et al. How to measure renal function in clinical practice. BMJ 2006; 333: 733-737.
6. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
7. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modication of diet in renal disease study equation for estimating glomerular ltration rate. Ann Intern Med 2006; 145: 247-254.
8. Wright JG, Boddy AV, Highley M et al. Estimation of glomerular ltration rate in cancer patients. Br J Cancer 2001; 84: 452-459.
9. Martin L, Chatelut E, Boneu A et al. Improvement of the Cockcroft-Gault equation for predicting glomerular ltration in cancer patients. Bull Cancer 1998; 85: 631-636.
10. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular ltration rate. Ann Intern Med 2009; 150: 604-612.
11. Kagoma YK, Weir MA, Iansavichus AV et al. Impact of estimated GFR reporting on patients, clinicians, and health-care systems: a systematic review. Am J Kindey Dis 2011; 57: 592-601.
12. Mosteller RD. Simplied calculation of body surface area. New Engl J Med 1987; 317: 1098.
13. Dooley MJ, Poole SG. Poor correlation between body surface area and glomerular ltration rate. Cancer Chemother Pharmacol 2000; 46: 523-526.
14. Dooley MJ, Singh S, Rischin D. Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients. Br J Cancer 2004; 90: 991-995.
15. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.16
16. Levey AS, Coresh J, Balk E et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classication, and stratication. Ann Intern Med 2003; 139: 137-147.
17. O'Callaghan CA, Shine B, Lasserson DS. Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting. BMJ 2011; e000308.
18. Barraclough LH, Field C, Wieringa G et al. Estimation of renal function - what is appropriate in cancer patients? Clin Oncol 2008; 20: 721-726.
19. Trobec K, Knez L, Mesko Brguljan P et al. Estimation of renal function in lung cancer patients. Lung Cancer 2011; 76: 397-402.
20. Ainsworth NL, Marshall A, Hatcher H et al. Evaluation of glomerular ltration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modication of Diet in Renal Disease (MDRD) formulae in oncology patients. Ann Oncol 2011; 23: 1845-1853.
21. Redal-Baigorri B, Stockholm KH, Rasmussen K et al. Estimation of kidney function in cancer patients. Danish Med Bull 2011; 58: 1-5.
22. Jennings S, de Lemos ML, Levin A et al. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. J Oncol Pharm Pract 2010; 16: 113-119.
23. de Lemos ML, Hsieh T, Hamata L et al. Evaluation of predictive formulae for glomerular ltration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol 2006; 103: 1063-1069.
24. Stevens LA, Padala S, Levey AS. Advances in glomerular ltration rate-estimating equations. Curr Opin Nephrol Hypertens 2010; 19: 298-307.
25. Collins IM, Roberts-Thomson R, Faulkner D et al. Carboplatin dosing in ovarian cancer problems and pitfalls. Int J Gynecol Cancer 2011; 21: 1213-1218.
26. Jones GR, Imam SK. Validation of the revised MDRD formula and the original Cockcroft and Gault formula for estimation of the glomerular ltration rate using Australian data. Pathology 2009; 41: 379-382.
27. Peake M, Whiting M. Measurement of serum creatinine-current status and future goals. Clin Biochem Rev 2006; 27: 173-184.
28. Gurney H, Shaw R. Obesity in dose calculation: a mouse or an elephant? J Clin Oncol 2007; 25: 4703-4704.
29. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009; 7: 99-108.
30. Huang SM, Temple R, Xiao S et al. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharm Ther 2009; 86: 475-479.
31. Lalonde RL, Wagner JA. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Clin Pharm Ther 2009; 86: 557-561.
32. Earley A, Miskulin D, Lamb EJ et al. Estimating equations for glomerular ltration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156: 785-795.
33. Poole SG, Dooley MJ, Rischin D. A comparison of bedside renal function estimates and measured glomerular ltration rate (Tc 99mDTPA clearance) in cancer patients. Ann Oncol 2002; 13: 949-955.